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Abstract 
Background: Hematological parameters have not received much attention in small animal models of infection, par-
ticularly at very early time points. We therefore studied changes in leukocyte and thrombocyte numbers in a mouse 
model of influenza A virus (IAV) infection, including measurements within the first 24 h after infection, and also assess-
ing effects, if any, of the infection/anesthesia procedure on these parameters.
Methods: DBA/2J and C57BL/6J mice (n = 5–8 per observation) were evaluated in a time course experiment of 
IAV infection, focusing on early time points. After anesthesia with ketamine/xylazine, a suspension of 2 × 103 focus 
forming units of the mouse-adapted IAV strain A/Puerto Rico/8/1934 (H1N1) in 20 µl sterile PBS, or 20 µl sterile PBS 
only (“mock treatment”), were instilled intranasally. Weight loss was assessed daily, and eight common hematological 
parameters and viral hemagglutinin (HA) mRNA expression were determined after 6, 12, 18, 24, 48 and 120 h.
Results: Hematological differences between the strains were apparent even in untreated mice. Infection-dependent 
changes, in particular increased granulocyte and decreased lymphocyte counts, were first detectable after 18 h in 
DBA/2J, were fully manifest in both strains at 48 h, and were usually more pronounced in the DBA/2J mice. In this 
strain, relative granulocyte and lymphocyte counts and the granulocyte/lymphocyte ratio correlated with viral HA 
mRNA expression and weight loss. In C57BL/6J, hematological parameters did not correlate with weight loss, but HA 
mRNA expression correlated weakly with total leukocyte counts, granulocyte/lymphocyte ratio, relative and absolute 
granulocyte counts, and relative lymphocyte counts. Significant changes due to mock treatment were mild and were 
detected only in C57BL/6J.
Conclusion: This study underscores the value of hematological parameters in monitoring disease evolution in the 
early phase of IAV infection, and likely other pathogens. The hematological response to infection may differ  
significantly among inbred mouse strains.
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Background
Hematological parameters are routinely assessed when 
evaluating infections in humans. Surprisingly, they are 
determined infrequently in small animal models of infec-
tious diseases (e.g. [1]). Influenza A virus (IAV) infection 
represents a common acute infection with a great dis-
ease burden in both human and veterinary medicine. 
The mouse represents a well-established small animal 
model of susceptibility to IAV infection in an adaptive 
host [2–4]. For instance, DBA/2J mice have been shown 
to be highly susceptible to the mouse-adapted IAV strain 
PR8 (A/Puerto Rico/8/1934 [H1N1]), whereas C57BL/6J 
mice are relatively resistant, as evidenced by less weight 
loss, less severe lung pathology, and a lower viral load. 
DBA/2J mice also mount a hyper-inflammatory response 
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with much stronger up-regulation of many immune 
response-dependent genes. As exemplified by the afore-
mentioned studies, work in murine models of IAV infec-
tion have concentrated on mRNA expression studies, and 
common peripheral blood cells have been assessed only 
rarely [5–7]. In a separate study, we have recently assessed 
immunological and hematological parameters as indica-
tors for disease severity in inbred mice infected with IAV 
strains of differential virulence [8]. We found that, among 
the 9 hematological indices assessed, the granulocyte/
lymphocyte ratio correlated best with disease severity 
independent of the mouse or virus strain used. However, 
in that study we did not evaluate very early time points 
or any effects due to the anesthesia/infection procedure. 
We therefore conducted the present study in order to 
characterize changes in hematological parameters in the 
very early phase of IAV infection and to test whether any 
effects due to anesthesia and intranasal installation of 
buffer only (“mock treatment”) occur in this early time 
window. We find that significant changes in hematologi-
cal parameters are first detected 18 h post infection (hpi) 
in DBA/2J and by 24 hpi in C57BL/6J mice, and are fully 
manifest in both strains by 48  hpi. Changes are consist-
ently more pronounced in the more susceptible DBA/2J 
strain, whereas a procedure-related (mock treatment) 
effect, albeit mild, is observed in the C57BL/6J strain only.
Methods
Animal procedures
Female 12–13-week old DBA/2J and C57BL/6J mice 
(n =  5–8 per time point and treatment) and the mouse-
adapted IAV strain PR8 (A/Puerto Rico/8/1934 [H1N1], 
Institute of Molecular Virology, University of Muenster, 
Germany; previously described in [4] and [9]) were used. 
All procedures were carried out essentially as described 
previously [10]. Briefly, mice were housed under pathogen-
free conditions, 5  animals per cage, making sure to keep 
IAV infected, mock treated, and control mice in separate 
cages. Mice were anesthetized with ketamine and xylazine. 
Intranasal infection was carried out using 2 ×  103 focus 
forming units (ffu) of IAV in 20 μl sterile PBS. Mock treat-
ment was identical to real anesthesia/infections except that 
vehicle only (sterile PBS), not containing virus, was used 
for intranasal instillation. Mice were weighed on day 0 just 
before induction of anesthesia and then once daily. Mice 
were killed by CO2 asphyxiation at 6, 12, 18, 24, 48, and 
120 h after infection or mock treatment. Untreated mice 
were used as t =  0  h control. RNA extracted from lung 
homogenates was used to measure expression of IAV HA 
mRNA expression. The same samples were used to meas-
ure various host-encoded transcripts, the results of which 
have been published separately [10]. The presented time 
course experiment served as an extension of the study 
published in [8] and was thus performed only once.
Ethics statement
All animal work was conducted according to the national 
guidelines of the animal welfare law in the Federal Repub-
lic of Germany and approved by the local regulatory 
authority (Niedersächsisches Landesamt für Verbrauch-
erschutz und Lebensmittelsicherheit [LAVES], Olden-
burg, Germany; permit number: 33.9.42502-04-051/09).
Hematological measurements
Whole blood was obtained immediately after CO2 
asphyxiation by cardiac puncture and collected in tubes 
containing EDTA as anticoagulant. Blood samples 
(50  μl) were analyzed with a VetScan HM5™ (Abaxis, 
Union City, CA, USA) hematology analyzer. The follow-
ing eight parameters were measured (units in brackets): 
white blood cell count (WBC [109/L]), absolute counts 
and percentages of lymphocytes (LYM [109/L]; LYM% 
[%]), monocytes (MON [109/L]; MON% [%]), and granu-
locytes (GRA [109/L]; GRA% [%]), and absolute platelet 
count (PLT [109/L]). The GRA/LYM ratio was calculated.
Data analysis
Data were analyzed using the R environment and program-
ming code [11]. Outliers in pulmonary expression of viral 
HA mRNA expression were excluded as described previ-
ously [10]. Differences (fold change, FC) were calculated 
by dividing the mean value of each condition by the mean 
value of the comparator or control. Analysis of variance 
(ANOVA) was used to test for trends throughout the time 
series, adjusting p values for false discovery rate (FDR). 
Tukey’s Honest Significant Differences Test for homogene-
ous variances was used for pairwise comparisons. Levene’s 
test was used to test variance equality. We used a signifi-
cance threshold of p ≤ 0.05. We used the R function power.
anova.test with power and p value thresholds of 0.8 and 
0.05, respectively, for post hoc sample size estimation.
Results
Kinetics of weight loss and IAV HA mRNA expression
As shown previously [4, 10], DBA/2J mice experienced sig-
nificant weight loss starting on day 2 and reached a maxi-
mum of about 25% by day 5 (Figure 1). Weight loss was less 
pronounced in C57BL/6J mice, as reflected by a 5–10% 
decrease starting by day 4. Between days 1 and 5, no sig-
nificant weight loss due to mock treatment was observed 
in either strain. HA mRNA was detected as early as 6 hpi, 
and differences between the mouse strains were already 
significant at 12 hpi. Overall, HA mRNA rose more rapidly 
and peaked earlier in DBA/2J than in C57BL/6J.
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Regulation of hematological parameters by infection 
and mock treatment
We measured absolute white blood cell (WBC) and plate-
let (PLT) counts, as well as absolute and relative granu-
locyte (GRA, GRA%), monocyte (MON, MON%), and 
lymphocyte (LYM, LYM%) counts. Differences between 
DBA/2J and C57BL/6J mice were clearly evident even in 
untreated mice in that GRA and GRA% were higher and 
LYM% was lower in DBA/2J, and the GRA/LYM ratio 
was substantially higher in DBA/2J (Table 1).
In infected DBA/2J mice, all eight tested parameters 
were regulated significantly across the time course 
(ANOVA, p  ≤  0.05) (Figure  2). In paired comparisons 
with 0 h, all parameters differed from 0 h at least at one 
time point (Tukey’s test, p ≤ 0.05). All parameters, except 
WBC and PLT, changed ≥1.5-fold. None of these param-
eters changed significantly after mock treatment.
In the C57BL/6J strain, only three parameters (GRA, 
GRA%, LYM%) changed significantly during infection 
(ANOVA, p ≤  0.05), two of which (GRA%, LYM%) dif-
fered in at least one time point from 0  h (Tukey’s test, 
p ≤  0.05), but the fold change (FC) of LYM% was <1.5. 
Significant changes were detected in DBA/2J at much 
earlier time points: an increase in GRA% and a decrease 
in LYM% were detected at 18 hpi, whereas any changes 
in C57BL/6J did not become significant until 48 hpi. The 
GRA/LYM ratio increased in both mouse strains from 
48 h onward, with markedly higher ratios being observed 
in the DBA/2J strain. Thus, infection-related changes in 
the leukocyte parameters were more time sensitive and 
pronounced in the DBA/2J strain. Mock treatment-asso-
ciated changes were exclusively detected in C57BL/6J 
mice and only affected WBC and LYM. These changes 
were relatively mild and were limited to the 6 and 12  h 
time points, but were significant according to both 
ANOVA and Tukey’s test (FC ≥1.5).
Sample size estimation
We then performed power calculations to estimate the 
number of mice needed to achieve statistical signifi-
cance to detect any regulation (at any time point) of each 
of the eight measured parameters and the GRA/LYM 
ratio across the time course. Results are summarized in 
Table 2. This analysis confirmed that the number of mice 
used was sufficient to detect infection-related changes 
in DBA/2J, but that up to 39 mice would be needed to 
detect additional mock treatment-related effects. For 
C57BL/6J mice, we estimated that about 10 infected mice 
(for WBC, LYM, MON, MON% and PLT) and 13 mock 
treated mice (all parameters except WBC and LYM) 
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Figure 1 Body weight and HA mRNA expression of mock-treated 
and infected DBA/2J and C57BL/6J mice. a Weight loss. Mice were 
weighed daily. b HA mRNA expression, measured by qRT-PCR in 
whole lung homogenate as outlined in “Methods”. Solid lines infec-
tion; dotted line mock treatment, colored area around line standard 
deviation. *p ≤ 0.05 compared to untreated mice (weight loss) or 
compared to 6 hpi (HA mRNA); ‡p ≤ 0.05 for difference between 
infected and mock treated mice at the given time point. All p values 
were determined with Tukey’s test. This figure is adapted from Ref. 
[10] and is shown here for the purpose of clarity.
Table 1 Selected hematological parameters in untreated 
mice
Values represent absolute (109 /L) and relative (%) mean blood counts.
P values (FDR adjusted): *** ≤0.001 and * ≤0.05.
Hematological 
parameter
DBA/2J (mean) C57BL/6J (mean) Ratio DBA/2J  
vs C57BL/6J
WBC 7.1 8.0 0.88
LYM 5.3 6.9 0.76
MON 0.22 0.15 1.5
GRA 1.6 0.94 1.7*
LYM% 74.5 86.6 0.86***
MON% 3.1 1.9 1.6
GRA% 22.4 11.5 1.9***
PLT 664.3 742.2 0.90
GRA/LYM 0.3 0.14 2.2***
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Figure 2 Changes in nine hematological parameters in mock-treated and infected DBA/2J and C57BL/6J mice. Data points were collected across 
the 5-day time course of IAV infection. Panels show mean values and variation of the data (standard deviation) of WBC (a, b), LYM (c, d), MON (e, 
f), GRA (g, h), LYM% (i, j), MON% (k, l), GRA% (m, n), PLT (o, p), and GRA/LYM ratio (q, r). Horizontal black lines indicate values of untreated mice 
(t = 0 h).  Left panel results obtained with the DBA/2J mouse strain. Right panel results obtained with the C57BL/6J mouse strain. Solid lines mice 
infected with 2 × 103 ffu IAV PR8 M in 20 µl sterile PBS. Interrupted lines mice undergoing the same anesthesia/infection procedure except that 
buffer only, not containing IAV, was used for the intranasal installation (“mock treatment”). *p ≤ 0.05 for difference between infected mice at the 
given time point with respect to 0 h; ∆p ≤ 0.05 for difference between mock treated and control (0 h) mice; ‡p ≤ 0.05 for difference between 
infected and mock treated mice at the given time point. All p values were determined with Tukey’s test.
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would be needed. Thus, more DBA/2J mice would be 
needed to detect any effects of mock treatment, but more 
C57BL/6J mice would be needed to detect additional 
infection-related effects.
Correlations with HA mRNA and weight loss
We then tested for correlations of the hematological param-
eters with measures of viral replication (expression of 
mRNA encoding the IAV HA protein) and clinical severity 
of the infection (weight loss). The GRA/LYM ratio, LYM%, 
and GRA% correlated significantly with HA mRNA expres-
sion in both mouse strains (Table  3). MON, MON%, and 
LYM correlated with HA mRNA expression in DBA/2J mice 
only. GRA and WBC correlated with HA mRNA expres-
sion in C57BL/6J mice only. GRA, GRA%, LYM%, and the 
GRA/LYM ratio correlated significantly with weight loss in 
DBA/2J mice. No significant correlation of any parameter 
with weight loss was observed in C57BL/6J mice.
Host strain‑specific temporal evolution of the 
hematological response to IAV infection
In a principal component analysis (PCA, Figure  3) based 
on the eight parameters (excluding the GRA/LYM ratio), 
time points and treatments tended to cluster according to 
mouse strain (black line) and infection status (green curve). 
As illustrated by the green curve, a cluster containing 
infected and mock treated time points could be identified 
easily in both mouse strains. Infected DBA/2J mice clearly 
segregated from this cluster at 18  hpi, whereas C57BL/6J 
mice did so much later (120 hpi) and to a markedly lesser 
extent. These results further support the notion that the 
overall hematological response to IAV infection was both 
more sensitive and pronounced in the DBA/2J strain.
Discussion
This detailed analysis of peripheral blood cell indices in 
the first 120 h of IAV infection in mice extends previous 
studies in that we included time points within the first 
24 hpi and also assessed any effects due to the anesthe-
sia/infection procedure. This analysis revealed that first 
significant infection-dependent changes are detected first 
in DBA/2J (18 hpi) and that procedure-dependent effects 
are detectable only in C57BL/6J mice; furthermore, it 
underscored the importance of the GRA/LYM ratio as a 
sensor of IAV infection.
Table 2 Sample size estimation
Values correspond to numbers of mice needed to detect a statistically significant 
difference across the time course (power = 0.8, p = 0.05, ANOVA). Values were 
rounded to the nearest higher integer.
Parameter DBA/2J C57BL/6J
Infection Mock Infection Mock
WBC 3 9 8 4
LYM 4 10 9 4
MON 4 39 11 12
GRA 3 7 4 19
LYM% 2 5 3 8
MON% 4 27 10 16
GRA% 2 7 3 9
PLT 3 9 12 17
GR/LYM 2 6 4 9
Table 3 Correlations of nine hematological parameters 
with HA mRNA expression and body weight
Values correspond to Spearman correlation coefficient in infected mouse strains, 
sorted by decreasing values in correlation with HA mRNA in DBA/2J mice. HA 
mRNA expression was measured with real-time RT-PCR in RNA isolated from 
lung homogenates. P values (FDR adjusted): * ≤0.05, ** ≤0.01, *** ≤0.001.
Hematological parameter HA mRNA Body weight
DBA/2J C57BL/6J DBA/2J C57BL/6J
GRA/LYM 0.60*** 0.37* −0.63** −0.24
GRA% 0.59*** 0.37* −0.64** −0.24
MON% 0.48** 0.18 −0.29 −0.29
MON 0.44* 0.18 −0.41 −0.19
GRA 0.35 0.43* −0.58* −0.02
PLT −0.11 −0.13 −0.32 −0.06
WBC −0.16 0.35* −0.35 0.35
LYM −0.46* 0.25 0.13 0.40
LYM% −0.61*** −0.41* 0.64** 0.28
Figure 3 Principal component analysis of eight hematologi-
cal parameters across the 5-day time course of IAV infection. The 
parameters WBC, LYM, MON, GRA, LYM%, MON%, GRA%, and PLT were 
measured in mock-treated and infected DBA/2J and C57BL/6J mice 
at 6, 12, 18, 24, 48, and 120 h, as well as in untreated mice (0 h). The 
analysis is based on the same data set as used for Figure 2. Each dot 
refers to the mean value of mice of one treatment as outlined in the 
legend adjacent to the box. The number inside each dot identifies the 
time (h) elapsed since 0 h. Including the GRA/LYM ratio or the third 
component did not improve discrimination (data not shown).
Page 6 of 7Preusse et al. BMC Res Notes  (2015) 8:225 
Differences between the mouse strains
The response to the infection in the DBA/2J strain 
evolved both sooner (18 hpi) and more briskly than in 
the C57BL/6J strain, in which first significant changes 
were observed not before 48 hpi, and the PCA revealed 
a global hematological reprogramming even later, i.e. 
at 120  hpi. What might account for these differences? 
Firstly, they might be due to differences in viral replica-
tion, as the DBA/2J strain is well known to be more per-
missive to IAV [4], which was confirmed by the more 
rapid and higher rise in HA mRNA levels in the pre-
sent study (Figure 1). In this model, the hematological 
changes would be driven primarily by the pathogen. On 
the other hand, the differences could also be explained 
by an inherently higher inflammatory propensity of the 
DBA/2J strain, which would fit our observation that 
GRA and GRA% values as well as the GRA/LYM ratio 
were higher in this strain even at baseline, and that 
some parameters such as MON and MON% changed in 
the DBA/2J strain only, despite clear evidence of IAV 
HA mRNA transcription in both host strains. We favor 
a combination of both models. LYM% correlated most 
negatively with HA mRNA expression in both mouse 
strains, indicating the presence of some common fea-
tures between the two mouse strains. We could not find 
a clear regulatory trend in PLT, but this may have been 
due to a technical error (for instance due to clot forma-
tion in samples at this time point) in the PLT measure-
ments at 48  hpi, which showed a lack of change even 
though the elevation at 24 and 120 hpi would imply an 
elevation at 48  hpi, too. However, in agreement with 
these negative findings, our previous study also did 
not reveal any association of PLT with disease sever-
ity in IAV infection in mice [8]. In contrast, the GRA/
LYM ratio clearly correlated with disease severity and 
differed greatly between the two mouse strains even 
at baseline. This is consistent with previous knowl-
edge that hematological parameters may differ among 
inbred mouse strains [12] and lends further support 
to the previously advanced notion that the GRA/LYM 
ratio is a reliable hematological marker for IAV infec-
tion in mice [8].
Procedure‑related effects
A hematological response to mock treatment was not 
detected in the DBA/2J strain. This was a surprising 
finding, since cytokine mRNA expression in the lung of 
DBA/2J mice shows a clear response to mock treatment 
and, in addition, is stronger than in the C57BL/6J strain 
[10]. The only observed effect due to mock treatment 
was a transient elevation in absolute leukocyte param-
eters in the C57BL/6J strain before 24  h. While there 
is no obvious explanation for the greater propensity of 
the C57BL/6J strain for procedure-related artefacts, 
it is conceivable that some links between airway stress 
and the immune response may be more reactive in this 
strain.
The value of hematological parameters as biomarkers 
of IAV infection in mice
The presented study sheds additional light on the value of 
using hematological parameters to follow the evolution 
of early IAV infection in mice. Traditionally, peripheral 
blood cytokines/chemokines or flow cytometric analyses 
of peripheral leukocyte populations have been used to 
follow the host response to viral infections in the periph-
ery, whereas the use of common hematological param-
eters (a much more cost- and labor-efficient read out) has 
not received much attention in research settings. This is 
all the more surprising as highly standardizable, easy-
to-use equipment and well validated reference values for 
many parameters are available. The most reliable infec-
tion-related changes in both mouse strains were observed 
in LYM% and GRA% at a time when the infection was rel-
atively well established (48 hpi), with the GRA/LYM ratio 
correlating best with pulmonary HA mRNA expression 
when considering both mouse strains. However, the first 
significant changes were detected as early as 18  hpi in 
the DBA/2J strain. This raises the possibility that certain 
leukocyte populations in peripheral blood might serve 
as surrogate markers for early establishment and subse-
quent progression of influenza infection in mice. While 
hematological parameters in established IAV infection 
in mice have been studied in sufficient cumulative num-
bers of mice [5–8], further studies featuring larger sam-
ple sizes and additional time points will be necessary to 
understand the value of these parameters within the first 
24 h better. Our results agree well with the findings of our 
recent study [8] in which peripheral blood indices were 
measured daily from 24 hpi until 14 days pi. That study 
demonstrated that the GRA/LYM ratio increased signif-
icantly as early as day 2 pi and stayed elevated through 
day 5. This ratio also correlated with disease severity, for 
instance when results were obtained from mice infected 
with IAV strains of different virulence or when the more 
susceptible DBA/2J and the C57BL/6J host strain were 
infected with the same IAV strain [8]. Taken together, 
these results suggest that hematological parameters 
(especially GRA/LYM and LYM%) can be used as robust 
biomarkers for progression of IAV infection starting 
at 48  hpi, whereas their use at earlier time points may 
depend more on the mouse strain used and will certainly 
benefit from additional validation. The increased GRA/
LYM and decreased LYM% clearly resulted from ris-
ing GRA counts accompanied by dropping LYM counts. 
Both granulocytosis (as part of the acute phase reaction) 
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and lymphopenia have been well documented in viral 
pneumonia in humans (e.g. [13]). The temporary drop in 
lymphocytes, which is the stronger determinant of the 
early changes in GRA/LYM and LYM% in both mouse 
strains (Figure 2) might be due to migration/retention of 
lymphocytes in lung and/or lymphoid tissue.
Value of the sample size calculations
For ethical and humanitarian reasons it is important to 
use the lowest number of laboratory animals needed to 
achieve statistical power. The analysis clearly showed 
that fewer DBA/2J than C57BL/6J mice were required to 
achieve statistical significance, suggesting that—assuming 
infection with equal infectious doses and viral strains—
smaller numbers of animals need to be used when work-
ing with the DBA/2J strain, thus allowing more efficient 
planning of experiments and using the optimal number 
of animals depending on the mouse strain to be used. 
Interestingly, it appears that even in the C57BL/6J strain, 
using approx. 10–12 animals per time point might suffice 
to study most infection-related changes in hematological 
parameters, a number that is similar to what is often used 
in mouse models of infectious diseases.
Conclusions
This study underscores the value of using hematologi-
cal parameters to track the evolution of IAV infection in 
mice, even in very early phases of infection. It also sug-
gests that “mock treatment” controls should be included 
in order to exclude any artefacts, albeit mild, arising from 
the infection/anesthesia procedure.
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